<DOC>
	<DOCNO>NCT00661583</DOCNO>
	<brief_summary>The purpose study study safety combination ranibizumab MMC v monotherapy MMC v intravitreal ranibizumab injection patient glaucoma .</brief_summary>
	<brief_title>Use Ranibizumab With Mitomycin C During Trabeculectomy</brief_title>
	<detailed_description>A common problem undergo trabeculectomy surgery create bleb ( blister bubble ) reduce intraocular pressure , scar opening . This scar prevents fluid drainage interfere proper function bleb . MMC ( Mitomycin C ) usually administer intraoperatively , reduce scar increase filtration . However , failure rate trabeculectomy remain high . Anti-VEGF ( Vascular endothelial growth factor ) agent use successfully case require bleb needling . The purpose study determine safety combination ranibizumab MMC v monotherapy MMC patient glaucoma . This open-label , Phase I/II safety study 30 patient randomize either treatment ranibizumab 0.5 mg intravitreally inject ( n=10 ) , combination ranibizumab 0.5mg intravitreally inject MMC ( 0.4 mg/ml 2 min ) eye trabeculectomy ( n=10 ) MMC therapy alone ( n=10 ) . For ranibizumab group , repeat injection ranibizumab 0.5mg may give PRN ( need ) 1 month hypervascularity neovascularization conjunctiva exists .</detailed_description>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>glaucoma undergo trabeculectomy 21 year age old pregnancy lactation condition investigator believe would impose significant hazard patient investigational therapy initiate history ocular surface disease cataract surgery past 6 month history active inflammatory , infectious idiopathic keratitis</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>trabeculectomy</keyword>
	<keyword>glaucoma</keyword>
	<keyword>ranibizumab</keyword>
</DOC>